Cancer therapy-related interstitial lung disease
Abstract. With the increasing utilization of cancer therapy, the incidence of lung injury associated with these treatments continues to rise. The recognition of pulmonary toxicity related to cancer therapy has become increasingly critical, for which interstitial lung disease (ILD) is a common cause...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer
2025-02-01
|
| Series: | Chinese Medical Journal |
| Online Access: | http://journals.lww.com/10.1097/CM9.0000000000003149 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832585109585264640 |
|---|---|
| author | Chengzhi Zhou Haiyi Deng Yilin Yang Fei Wang Xinqing Lin Ming Liu Xiaohong Xie Tao Luan Nanshan Zhong Peifang Wei |
| author_facet | Chengzhi Zhou Haiyi Deng Yilin Yang Fei Wang Xinqing Lin Ming Liu Xiaohong Xie Tao Luan Nanshan Zhong Peifang Wei |
| author_sort | Chengzhi Zhou |
| collection | DOAJ |
| description | Abstract. With the increasing utilization of cancer therapy, the incidence of lung injury associated with these treatments continues to rise. The recognition of pulmonary toxicity related to cancer therapy has become increasingly critical, for which interstitial lung disease (ILD) is a common cause of mortality. Cancer therapy-related ILD (CT-ILD) can result from a variety of treatments including chemotherapy, targeted therapy, immune checkpoint inhibitors, antibody–drug conjugates, and radiotherapy. CT-ILD may progress rapidly and even be life-threatening; therefore, prompt diagnosis and timely treatment are crucial for effective management. This review aims to provide valuable information on the risk factors associated with CT-ILD; elucidate its underlying mechanisms; discuss its clinical features, imaging, and histological manifestations; and emphasize the clinical-related views of its diagnosis. In addition, this review provides an overview of grading, typing, and staging treatment strategies used for the management of CT-ILD. |
| format | Article |
| id | doaj-art-fa684a3e025d4d16af753f36a16f3d6c |
| institution | Kabale University |
| issn | 0366-6999 2542-5641 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Wolters Kluwer |
| record_format | Article |
| series | Chinese Medical Journal |
| spelling | doaj-art-fa684a3e025d4d16af753f36a16f3d6c2025-01-27T06:04:15ZengWolters KluwerChinese Medical Journal0366-69992542-56412025-02-01138326427710.1097/CM9.0000000000003149202502050-00004Cancer therapy-related interstitial lung diseaseChengzhi Zhou0Haiyi Deng1Yilin Yang2Fei Wang3Xinqing Lin4Ming Liu5Xiaohong Xie6Tao Luan7Nanshan Zhong8Peifang Wei1 State Key Laboratory of Respiratory Diseases, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Department of Pulmonary and Critical Care Medicine, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510120, China2 KingMed School of Laboratory Medicine, Guangzhou Medical University, Guangzhou, Guangdong 511436, China1 State Key Laboratory of Respiratory Diseases, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Department of Pulmonary and Critical Care Medicine, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510120, China1 State Key Laboratory of Respiratory Diseases, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Department of Pulmonary and Critical Care Medicine, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510120, China1 State Key Laboratory of Respiratory Diseases, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Department of Pulmonary and Critical Care Medicine, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510120, China1 State Key Laboratory of Respiratory Diseases, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Department of Pulmonary and Critical Care Medicine, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510120, China1 State Key Laboratory of Respiratory Diseases, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Department of Pulmonary and Critical Care Medicine, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510120, China1 State Key Laboratory of Respiratory Diseases, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Department of Pulmonary and Critical Care Medicine, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510120, China1 State Key Laboratory of Respiratory Diseases, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Department of Pulmonary and Critical Care Medicine, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510120, ChinaAbstract. With the increasing utilization of cancer therapy, the incidence of lung injury associated with these treatments continues to rise. The recognition of pulmonary toxicity related to cancer therapy has become increasingly critical, for which interstitial lung disease (ILD) is a common cause of mortality. Cancer therapy-related ILD (CT-ILD) can result from a variety of treatments including chemotherapy, targeted therapy, immune checkpoint inhibitors, antibody–drug conjugates, and radiotherapy. CT-ILD may progress rapidly and even be life-threatening; therefore, prompt diagnosis and timely treatment are crucial for effective management. This review aims to provide valuable information on the risk factors associated with CT-ILD; elucidate its underlying mechanisms; discuss its clinical features, imaging, and histological manifestations; and emphasize the clinical-related views of its diagnosis. In addition, this review provides an overview of grading, typing, and staging treatment strategies used for the management of CT-ILD.http://journals.lww.com/10.1097/CM9.0000000000003149 |
| spellingShingle | Chengzhi Zhou Haiyi Deng Yilin Yang Fei Wang Xinqing Lin Ming Liu Xiaohong Xie Tao Luan Nanshan Zhong Peifang Wei Cancer therapy-related interstitial lung disease Chinese Medical Journal |
| title | Cancer therapy-related interstitial lung disease |
| title_full | Cancer therapy-related interstitial lung disease |
| title_fullStr | Cancer therapy-related interstitial lung disease |
| title_full_unstemmed | Cancer therapy-related interstitial lung disease |
| title_short | Cancer therapy-related interstitial lung disease |
| title_sort | cancer therapy related interstitial lung disease |
| url | http://journals.lww.com/10.1097/CM9.0000000000003149 |
| work_keys_str_mv | AT chengzhizhou cancertherapyrelatedinterstitiallungdisease AT haiyideng cancertherapyrelatedinterstitiallungdisease AT yilinyang cancertherapyrelatedinterstitiallungdisease AT feiwang cancertherapyrelatedinterstitiallungdisease AT xinqinglin cancertherapyrelatedinterstitiallungdisease AT mingliu cancertherapyrelatedinterstitiallungdisease AT xiaohongxie cancertherapyrelatedinterstitiallungdisease AT taoluan cancertherapyrelatedinterstitiallungdisease AT nanshanzhong cancertherapyrelatedinterstitiallungdisease AT peifangwei cancertherapyrelatedinterstitiallungdisease |